Ironwood Pharmaceuticals (IRWD) Short term Debt (2012 - 2026)

Ironwood Pharmaceuticals has disclosed Short term Debt across 15 years of filings, most recently posting $199.9 million for Q1 2026.

• In Q1 2026, Short term Debt changed N/A year-over-year to $199.9 million; the TTM figure through Mar 2026 stood at $199.9 million (changed N/A YoY), while the FY2025 annual figure was $199.7 million, changed N/A from the prior year.
• Short term Debt came in at $199.9 million for Q1 2026 at Ironwood Pharmaceuticals, roughly flat from $199.7 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $199.9 million in Q1 2026 to a low of $1000.0 in Q3 2022.
• Average Short term Debt over 5 years is $143.1 million, with a median of $199.3 million recorded in 2023.
• Year-over-year, Short term Debt sank 100.0% in 2022 and jumped 19932000.0% in 2023.
• Over 5 years, Short term Debt stood at $19000.0 in 2022, then jumped by 1050215.79% to $199.6 million in 2023, then increased by 0.12% to $199.8 million in 2024, then declined by 0.06% to $199.7 million in 2025, then advanced by 0.09% to $199.9 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $199.9 million in Q1 2026, $199.7 million in Q4 2025, and $199.5 million in Q3 2025.